| Date | Title | Description |
| 20.02.2026 | Fixed-duration Calquence combo approved in US | Fixed-duration Calquence combo approved in US
Fri, Feb 20, 2026 08:00 CET Report this content
20 February 2026
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic ... |
| 29.01.2026 | AstraZeneca invests $15bn in China through 2030 | AstraZeneca invests $15bn in China through 2030
Thu, Jan 29, 2026 11:24 CET Report this content
29 January 2026
AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines
Landmark in... |
| 08.12.2025 | China Releases First Novel Drugs List for Commercial Insurance, With CAR-T Therapies Leading the Way | (Yicai) Dec. 8 -- China introduced its first Commercial Health Insurance Innovative Drug List that includes five chimeric antigen receptor-T cell therapies, which re-engineer a patient's own white blood cells to recognize and attack cancer,... |
| 01.08.2025 | Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland | HONG KONG SAR – Media OutReach Newswire – 1 August 2025 – Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences re... |
| 06.06.2025 | Fixed-duration Calquence approved in EU for 1L CLL | Fixed-duration Calquence approved in EU for 1L CLL
Fri, Jun 06, 2025 08:00 CET Report this content
06 June 2025
Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting
A... |
| 15.05.2025 | Vivo Capital: Public Fund Closed With Over $740 Million In Commitments | Vivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund... |
| 29.04.2025 | AstraZeneca's Calquence: A New Dawn for CLL Treatment in Europe | AstraZeneca is on the brink of a breakthrough. The European Medicines Agency (EMA) has recommended the approval of a fixed-duration regimen of Calquence (acalabrutinib) for treating chronic lymphocytic leukaemia (CLL). This recommendation, ... |
| 29.04.2025 | Fixed-duration Calquence recommended in EU for CLL | Fixed-duration Calquence recommended in EU for CLL
Tue, Apr 29, 2025 08:10 CET Report this content
29 April 2025
Fixed-duration Calquence-based regimens recommended for approval
in the EU by CHMP for 1st-line chronic lymphocytic leukaemia
R... |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results
Thu, Apr 25, 2024 08:00 CET Report this content
AstraZeneca
25 April 2024
Q1 2024 results
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Revenue and EPS summary
Q1 2024 % ... |
| 26.12.2023 | AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases | - |
| 06.09.2023 | Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 6, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to dev... |
| 07.08.2023 | Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing | - |
| 07.08.2023 | Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors | Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Mana... |
| 04.06.2023 | Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting | Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) popula... |
| 15.05.2023 | Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) | Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease
GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of aut... |
| 12.05.2023 | Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress | First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-A... |
| 26.04.2023 | Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to de... |
| 28.02.2023 | Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference | SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to dev... |
| 27.02.2023 | Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023 | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to de... |
| 13.02.2023 | Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma | Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F
Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb.... |
| 03.02.2023 | Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma | BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies
Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023
SAN DIEGO ... |
| 11.12.2022 | Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate | BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition
SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotec... |
| 11.12.2022 | Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate | BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition
SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 11, 2022 /PRNewswire/ -- Gracell Biotec... |
| 23.11.2022 | Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Nov. 23, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing hi... |
| 16.11.2022 | Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award | FasTCAR next-day manufacturing autologous CAR-T platform recognized with prestigious biotech innovation award
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 16, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" ... |
| 03.11.2022 | Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition | BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell"... |
| 31.10.2022 | Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious... |
| 24.10.2022 | Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing hi... |
| 17.10.2022 | Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia | Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company&quo... |
| 14.09.2022 | Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing h... |
| 29.08.2022 | Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 29, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing hi... |
| 02.08.2022 | Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022 | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious ... |
| 01.08.2022 | Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer | Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "C... |
| 26.07.2022 | Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference | SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, July 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing hi... |
| 19.07.2022 | Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer | SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to deve... |
| 14.06.2022 | Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences | SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, June. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highl... |
| 03.06.2022 | Gracell Biotechnologies Schedules Clinical Update Call After EHA2022 | SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, June. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious ... |
| 19.05.2022 | Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences | SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly ... |
| 12.05.2022 | Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress | SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to develop... |
| 28.04.2022 | Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting | Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma
SAN DIEGO, Calif. and SUZHOU, China,... |
| 14.04.2022 | Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting | PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highl... |
| 09.04.2022 | Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL | Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL
PALO ALTO, Calif. and SUZHOU, China, April 9, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell&... |
| 09.03.2022 | Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 | Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy
PALO ALTO, Calif. and SUZHOU, China, March 9, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Grac... |
| 22.02.2022 | Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform | SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highl... |
| 17.02.2022 | Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma | SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly... |
| 12.01.2022 | Gracell Biotechnologies Unveils Innovation Center in U.S. | SUZHOU, China and PALO ALTO, Calif., Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highl... |
| 16.12.2021 | Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index | SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to de... |
| 23.11.2021 | Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan | SUZHOU, China and PALO ALTO, Calif., Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highl... |
| 19.11.2021 | Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma | SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious... |
| 15.11.2021 | Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update | SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and... |
| 04.11.2021 | Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting | SUZHOU and SHANGHAI, China, and PALO ALTO, California, Nov. 4, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficaci... |
| 16.08.2021 | Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors | SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious... |
| 26.05.2021 | Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of... | SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficaciou... |
| 20.05.2021 | Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 | SUZHOU, China and PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable... |
| 17.05.2021 | GRACELL BIOTECHNOLOGIES INC.
Gracell Biotechnologies : Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update | Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting
Signed agreement with Lonza to manufacture FasTCAR-enabled product candidates in... |
| 11.05.2021 | Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer | SUZHOU, China and PALO ALTO, California, China, May 11, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and... |
| 31.03.2021 | GRACELL BIOTECHNOLOGIES INC.
Gracell Biotechnologies : Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment ... | SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell t... |
| 05.12.2020 | Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mu... | |
| 04.11.2020 | Gracell Biotechnologies Announces Two Oral Presentations at the ASH Annual Meeting and Exposition 2020 | |
| 29.10.2020 | Gracell Biotechnologies Raises $100M in Series C Funding | Gracell Biotechnologies Inc., a Shangai, China-based clinical-stage biopharmaceutical company dedicated to developing cell therapies for the treatment of cancer, secured $100m in Series C funding.
The round is led by Wellington Management C... |
| 29.10.2020 | Chinese biotech firm Gracell nets $100m from Wellington, OrbiMed, others | Chinese clinical-stage biopharmaceutical firm Gracell Biotechnologies Inc. has completed a $100 million Series C round co-led by the US investment company Wellington Management, New York-based OrbiMed Healthcare Fund Management, and VC firm... |
| 28.10.2020 | Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies | |
| 27.02.2019 | China's Gracell Biotechnology Rakes In USD85 Million in Series B | (Yicai Global) Feb. 26 -- Emerging cell therapy company Gracell Biotechnology has closed its series B funding from which it netted USD85 million.
The proceeds will push clinical trials of its next-generation cancer immunotherapy drugs, tech... |
| 27.02.2019 | China's Gracell Biotechnology Rakes In USD85 Million in Series B | (Yicai Global) Feb. 26 -- Emerging cell therapy company Gracell Biotechnology has closed its series B funding from which it netted USD85 million.
The proceeds will push clinical trials of its next-generation cancer immunotherapy drugs, tech... |
| 26.02.2019 | Term Sheet — Tuesday, February 26 | MO’ MONEY, MO’ PROBLEMS
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
PE funds produced another surge in investment value in 2018, capping the strongest five-year stretch in the indu... |
| 25.02.2019 | Gracell Biotechnologies Completes $85M in Series B Funding | Gracell Biotechnologies, Co., Ltd., a Suzhou, China-based innovative biomedical company, completed an $85m Series B funding.
The round was led by Temasek with participation from Lilly Asia Ventures, Kington Capital, King Star Capital and Ch... |
